GPCR vs TYRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GPCR · Structure Therapeutics$20.35 ▲ 6.66%
TYRA · TYRA BIOSCIENCES, INC.$21.15 ▲ 1.24%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GPCR -40.0%
- TYRA +45.9%
Head to head
| Metric | GPCR | TYRA |
|---|---|---|
| Price | $20.35 | $21.15 |
| Change today | ▲ 6.66% | ▲ 1.24% |
| Market cap | $1.45B | $1.45B |
| Return, 3 months | -62.2% | -19.4% |
| Return, year to date | -70.7% | -19.6% |
| Return, 1 year | -38.0% | +47.7% |
| P/E (TTM) | – | – |
| P/B | 1.1 | 4.1 |
| P/E percentile vs own 5y | 94th | 59th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -72.2% | -62.1% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -20.2% | -45.3% |
| Analyst target vs. price | +420.0% | +124.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 30 | 49 |
| 30-day volatility | 58.3% | 41.9% |
| Max drawdown, 1 year | -79.7% | -53.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TYRA is the largest of the group by market value.
- TYRA has returned the most over the past year.
- TYRA has been the calmest stock over the last 30 days.